ArticleVaccines2025

A Phase II Random, Double-Blind, Placebo-Controlled Study of the Safety and Immunogenicity of a Recombinant G Protein-Based Respiratory Syncytial Virus Vaccine in Healthy Older Adults.

Lunan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.